Free tool
FAERS Monitor: Diclegis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021876 or its brand name (Diclegis, Doxylamine Succinate, Pyridoxine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
409
Serious
211
52% of reports
Hospitalization
86
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- maternal exposure during pregnancy50
- premature delivery43
- exposure during pregnancy40
- foetal exposure during pregnancy36
- nausea33
- somnolence32
- vomiting31
- drug ineffective24
- off label use22
- abortion spontaneous21
- headache20
- dizziness13
- migraine13
- pre-eclampsia13
- anxiety12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 31 |
| 2016 | 67 |
| 2017 | 77 |
| 2018 | 76 |
| 2019 | 41 |
| 2020 | 26 |
| 2021 | 15 |
| 2022 | 11 |
| 2023 | 16 |
| 2024 | 11 |
| 2025 | 19 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,750 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pre-eclampsiaSignal | 13 | 141.1 | 82.6 | 1,666 |
| premature deliverySignal | 43 | 139.2 | 104.9 | 5,753 |
| exposure during pregnancySignal | 40 | 33.1 | 24.7 | 1,217 |
| maternal exposure during pregnancySignal | 50 | 28.9 | 22.3 | 1,322 |
| abortion spontaneousSignal | 21 | 27.0 | 17.8 | 500 |
| foetal exposure during pregnancySignal | 36 | 22.8 | 16.7 | 731 |
| somnolenceSignal | 32 | 8.2 | 5.9 | 196 |
| migraineSignal | 13 | 7.0 | 4.1 | 61 |
| vomitingSignal | 31 | 3.4 | 2.4 | 51 |
| anxietySignal | 12 | 2.2 | 1.2 | 7 |
| nauseaSignal | 33 | 2.1 | 1.5 | 20 |
| headache | 20 | 1.6 | 1.1 | 5 |
| dizziness | 13 | 1.3 | 0.8 | 1 |
| off label use | 22 | 1.3 | 0.9 | 1 |
| drug ineffective | 24 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.